Early extrapyramidal side-effects as risk factors for later tardive dyskinesia: a prospective study
- PMID: 15209837
- DOI: 10.1080/j.1440-1614.2004.01382.x
Early extrapyramidal side-effects as risk factors for later tardive dyskinesia: a prospective study
Abstract
Objective: To determine whether acute neuroleptic-induced parkinsonism and akathisia were risk factors for the later development of tardive dyskinesia (TD) in patients on typical neuroleptics.
Method: Of 100 subjects examined for parkinsonism and akathisia after the initiation of typical neuroleptic medication, 78 were followed up for TD after a mean 41.2 months.
Results: Nine (11.5%) subjects were diagnosed with TD, predominantly manifesting as oro-facial dyskinesia. They had greater severity of parkinsonism and akathisia at baseline, and a larger neuroleptic load, than those who did not develop TD. On regression analyses, parkinsonism at baseline was a significant predictor of later TD. Examined independently of parkinsonism, akathisia severity at 2 weeks was also a significant predictor of later TD.
Conclusions: Acute drug-induced parkinsonism and akathisia are both predictors of TD, with parkinsonism having greater predictive value. Acute and tardive extrapyramidal syndromes may share vulnerability factors.
Similar articles
-
Movement Disorders and Mortality in Severely Mentally Ill Patients: The Curacao Extrapyramidal Syndromes Study XIV.Schizophr Bull. 2022 Jun 21;48(4):766-773. doi: 10.1093/schbul/sbac037. Schizophr Bull. 2022. PMID: 35486807 Free PMC article.
-
Extrapyramidal syndromes in neuroleptic-treated patients: prevalence, risk factors, and association with tardive dyskinesia.J Clin Psychopharmacol. 1999 Jun;19(3):203-8. doi: 10.1097/00004714-199906000-00002. J Clin Psychopharmacol. 1999. PMID: 10350026
-
The prevalence of metoclopramide-induced tardive dyskinesia and acute extrapyramidal movement disorders.Arch Intern Med. 1993 Jun 28;153(12):1469-75. Arch Intern Med. 1993. PMID: 8512437
-
Clinical relationship of extrapyramidal symptoms and tardive dyskinesia.Can J Psychiatry. 1994 Nov;39(9 Suppl 2):S76-80. Can J Psychiatry. 1994. PMID: 7874668 Review.
-
The problem of tardive akathisia.Brain Cogn. 1993 Sep;23(1):102-9. doi: 10.1006/brcg.1993.1048. Brain Cogn. 1993. PMID: 8105819 Review.
Cited by
-
Assesment of Risk Factors for Tardive Dyskinesia.Psychopharmacol Bull. 2020 Jul 23;50(3):36-46. Psychopharmacol Bull. 2020. PMID: 32733110 Free PMC article.
-
Incidence of tardive dyskinesia with atypical versus conventional antipsychotic medications: a prospective cohort study.J Clin Psychiatry. 2010 Apr;71(4):463-74. doi: 10.4088/JCP.07m03890yel. Epub 2010 Feb 9. J Clin Psychiatry. 2010. PMID: 20156410 Free PMC article.
-
Guideline for pharmacological treatment of schizophrenia 2022.Neuropsychopharmacol Rep. 2025 Mar;45(1):e12497. doi: 10.1002/npr2.12497. Epub 2024 Nov 25. Neuropsychopharmacol Rep. 2025. PMID: 39587785 Free PMC article. No abstract available.
-
Japanese Society of Neuropsychopharmacology: "Guideline for Pharmacological Therapy of Schizophrenia".Neuropsychopharmacol Rep. 2021 Sep;41(3):266-324. doi: 10.1002/npr2.12193. Epub 2021 Aug 12. Neuropsychopharmacol Rep. 2021. PMID: 34390232 Free PMC article. No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources